HRP20210256T1 - Genetski modificirani mišji receptor t-stanice - Google Patents
Genetski modificirani mišji receptor t-stanice Download PDFInfo
- Publication number
- HRP20210256T1 HRP20210256T1 HRP20210256TT HRP20210256T HRP20210256T1 HR P20210256 T1 HRP20210256 T1 HR P20210256T1 HR P20210256T T HRP20210256T T HR P20210256TT HR P20210256 T HRP20210256 T HR P20210256T HR P20210256 T1 HRP20210256 T1 HR P20210256T1
- Authority
- HR
- Croatia
- Prior art keywords
- cell
- rodent
- human
- variable
- deletion
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title claims 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims 6
- 241000699670 Mus sp. Species 0.000 title 1
- 241000283984 Rodentia Species 0.000 claims 29
- 210000004027 cell Anatomy 0.000 claims 24
- 210000001744 T-lymphocyte Anatomy 0.000 claims 21
- 108090000623 proteins and genes Proteins 0.000 claims 21
- 238000012217 deletion Methods 0.000 claims 14
- 230000037430 deletion Effects 0.000 claims 14
- 238000000034 method Methods 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- GTJASUYQSYEAFD-NPRBSQQLSA-N 102643-50-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)N)[C@@H](C)O)C1=CC=CC=C1 GTJASUYQSYEAFD-NPRBSQQLSA-N 0.000 claims 1
- 108700042077 T-Cell Receptor beta Genes Proteins 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 108010050138 synthetic joining segment peptide Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0387—Animal model for diseases of the immune system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (17)
1. Izolirana stanica glodavca, naznačena time, da obuhvaća:
najmanje jedan nepreuređeni Vα-segment varijabilne regije ljudske T-stanice i najmanje jedan nepreuređeni Jα-segment varijabilne regije ljudske T-stanice, koji su operabilno povezani s konstantnim genskim TCRα-slijedom glodavca, na endogenom varijabilnom genskom TCRα-lokusu glodavca, i/ili
najmanje jedan nepreuređeni Vβ-segment varijabilne regije ljudske T-stanice, najmanje jedan nepreuređeni Dβ-segment varijabilne regije ljudske T-stanice, i najmanje jedan nepreuređeni Jβ-segment varijabilne regije ljudske T-stanice, koji su operabilno povezani s konstantnim genskim TCRβ-slijedom glodavca, na endogenom varijabilnom genskom TCRβ-lokusu glodavca,
pri čemu su nepreuređeni segmenti varijabilne regije ljudske T-stanice sposobni za preuređivanje u T-stanici, u svrhu tvorbe gena koji kodiraju varijabilne domene receptora ljudske T-stanice, koje se specifično vežu na antigen od interesa.
2. Izolirana stanica glodavca prema patentnom zahtjevu 1, naznačena time, da stanica glodavca sadrži deleciju odabranu iz skupine koja se sastoji od (a) delecije svih endogenih genskih Vα-segmenata, (b) delecije svih endogenih genskih Jα-segmenata, i (c) njihove kombinacije i/ili time, da stanica glodavca sadrži deleciju odabranu iz skupine koja se sastoji od (a) delecije svih endogenih genskih Vβ-segmenata, (b) delecije svih endogenih genskih Dβ-segmenata, (c) delecije svih endogenih genskih Jβ-segmenata, i (d) njihove kombinacije.
3. Izolirana stanica glodavca prema bilo kojem od patentnih zahtjeva 1 do 2, naznačena time, da stanica jest matična stanica embrija.
4. Izolirana T-stanica glodavca, naznačena time, da na endogenom varijabilnom genskom TCRα-lokusu, sadrži preuređeni ljudski TCR Vα/Jα-slijed i/ili na endogenom varijabilnom genskom TCRβ-lokusu, sadrži preuređeni ljudski TCR Vβ/Dβ/Jβ-slijed, gdje T-stanica eksprimira receptor T-stanice koji sadrži varijabilnu ljudsku TCRα-domenu operabilno povezanu s konstantnom TCRα-regijom glodavca, i/ili varijabilnu ljudsku TCRβ-domenu operativno povezanu s konstantnom TCRβ-regijom glodavca, na svojoj staničnoj površini.
5. Izolirana T-stanica glodavca prema patentnom zahtjevu 4, naznačena time, da T-stanica jest CD4+ T-stanica, CD8+ T-stanica, hibridom ili kvadrom izveden iz CD4+ T-stanice, ili hibridom ili kvadrom izveden iz CD8+ T-stanice.
6. Izolirana stanica ili T-stanica glodavca prema bilo kojem od patentnih zahtjeva 1 do 5, naznačena time, da glodavac je štakor.
7. Izolirana stanica ili T-stanica glodavca prema bilo kojem od patentnih zahtjeva 1 do 5, naznačena time, da glodavac je miš.
8. Sustav in vitro, naznačen time, da sadrži stanicu u skladu s bilo kojim od patentnih zahtjeva 1 do 7.
9. Stanični kompleks in vitro, naznačen time, da obuhvaća prvu stanicu u skladu s bilo kojim od patentnih zahtjeva 4 do 7 i drugu stanicu, pri čemu je druga stanica antigen koji predstavlja stanicu koja eksprimira ljudsku ili humaniziranu MHC molekulu.
10. Stanični kompleks in vitro prema patentnom zahtjevu 9, naznačen time, da druga stanica je ljudska stanica ili stanica glodavca.
11. Postupak proizvodnje genetski modificiranog glodavca, naznačen time, da obuhvaća:
modificiranje endogenog varijabilnog genskog TCRα-lokusa glodavca, u svrhu obuhvaćanja najmanje jednog nepreuređenog Vα-segmenta varijabilne regije ljudske T-stanice i najmanje jednog nepreuređenog Jα-segmenta varijabilne regije ljudske T-stanice, koji su operabilno povezani s konstantnim genskim TCRα-slijedom glodavca, i/ili
modificiranje endogenog varijabilnog genskog TCRβ-lokusa glodavca, u svrhu obuhvaćanja najmanje jednog nepreuređenog Vβ-segmenta varijabilne regije ljudske T-stanice, najmanje jednog nepreuređenog Dβ-segmenta varijabilne regije ljudske T-stanice, i najmanje jednog nepreuređenog Jβ-segmenta varijabilne regije ljudske T-stanice, koji su operabilno povezani s konstantnim genskim TCRβ-slijedom glodavca,
pri čemu su nepreuređeni segmenti varijabilne regije ljudske T-stanice sposobni za preuređivanje u svrhu tvorbe gena koji kodiraju varijabilne
domene receptora ljudske T-stanice, uključujući domene koje se specifično vežu na antigen od interesa.
12. Postupak prema patentnom zahtjevu 11, naznačen time, da glodavac sadrži deleciju odabranu iz skupine koja se sastoji od (a) delecije svih endogenih genskih Vα-segmenata, (b) delecije svih endogenih genskih Jα-segmenata, i (c) njihove kombinacije i/ili time, da glodavac sadrži deleciju odabranu iz skupine koja se sastoji od (a) delecije svih endogenih genskih Vβ-segmenata, (b) delecije svih endogenih genskih Dβ-segmenata, (c) delecije svih endogenih genskih Jβ-segmenata, i (d) njihove kombinacije.
13. Postupak prema bilo kojem od patentnih zahtjeva 11 do 12, naznačen time, da glodavac je štakor.
14. Postupak prema bilo kojem od patentnih zahtjeva 11 do 12, naznačen time, da glodavac je miš.
15. Postupak prema patentnom zahtjevu 14, naznačen time, da se modifikacija radi u samo jednoj ES stanici, i samo jedna ES stanica se uvodi u embrij miša u svrhu stvaranja miša.
16. Postupak za dobivanje slijeda nukleinske kiseline koji kodira ljudsku varijabilnu TCR-domenu, naznačen time, da obuhvaća:
određivanje slijeda nukleinske kiseline ljudske varijabilne TCR-regije koja je eksprimirana pomoću izolirane stanice glodavca u skladu s bilo kojim od patentnih zahtjeva 4 do 7.
17. Postupak za proizvodnju receptora T-stanice, naznačen time, da obuhvaća:
dobivanje izolirane stanice glodavca u skladu s bilo kojim od patentnih zahtjeva 4 do 7;
izoliranje slijeda nukleinske kiseline koji kodira barem ljudsku varijabilnu TCR-domenu koja je eksprimirana pomoću izolirane stanice glodavca;
kloniranje slijeda nukleinske kiseline u nukleotidni konstrukt, i ekspresija u stanici navedenog receptora T-stanice.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552582P | 2011-10-28 | 2011-10-28 | |
| US201261621198P | 2012-04-06 | 2012-04-06 | |
| US201261700908P | 2012-09-14 | 2012-09-14 | |
| EP18176096.8A EP3424947B1 (en) | 2011-10-28 | 2012-10-26 | Genetically modified t cell receptor mice |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210256T1 true HRP20210256T1 (hr) | 2021-04-02 |
Family
ID=47178340
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181626TT HRP20181626T1 (hr) | 2011-10-28 | 2018-10-10 | Genetski modificirani miševi receptora t-stanice (tcr-miševi) |
| HRP20210256TT HRP20210256T1 (hr) | 2011-10-28 | 2021-02-15 | Genetski modificirani mišji receptor t-stanice |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181626TT HRP20181626T1 (hr) | 2011-10-28 | 2018-10-10 | Genetski modificirani miševi receptora t-stanice (tcr-miševi) |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US9113616B2 (hr) |
| EP (3) | EP3795587A1 (hr) |
| JP (7) | JP6254528B2 (hr) |
| KR (5) | KR102321909B1 (hr) |
| CN (5) | CN114891798A (hr) |
| AU (4) | AU2012327204B2 (hr) |
| BR (1) | BR112014009203B1 (hr) |
| CA (1) | CA2853707A1 (hr) |
| CY (2) | CY1120945T1 (hr) |
| DK (2) | DK3424947T3 (hr) |
| ES (2) | ES2858978T3 (hr) |
| HK (1) | HK1198171A1 (hr) |
| HR (2) | HRP20181626T1 (hr) |
| HU (1) | HUE053444T2 (hr) |
| IL (3) | IL274914B2 (hr) |
| IN (1) | IN2014CN03890A (hr) |
| LT (2) | LT2771357T (hr) |
| MX (1) | MX353134B (hr) |
| PL (2) | PL3424947T3 (hr) |
| PT (2) | PT2771357T (hr) |
| RS (2) | RS61455B1 (hr) |
| RU (1) | RU2661106C2 (hr) |
| SG (2) | SG11201401030WA (hr) |
| SI (2) | SI3424947T1 (hr) |
| WO (1) | WO2013063361A1 (hr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3424947T3 (da) * | 2011-10-28 | 2021-02-22 | Regeneron Pharma | Genmodificerede t-celle-receptor-mus |
| US20150073043A1 (en) * | 2012-01-19 | 2015-03-12 | Institut Pasteur Of Shanghai, Chinese Academy Of Sciences | Use of phosphorylation pathway-related factor in regulating function of regulatory t cell |
| EP2847335B1 (en) | 2012-04-25 | 2018-06-27 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated targeting with large targeting vectors |
| GB2508414A (en) * | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| PT3456831T (pt) | 2013-04-16 | 2021-09-10 | Regeneron Pharma | Modificação alvejada do genoma de rato |
| CN105980568B (zh) | 2013-12-11 | 2019-12-03 | 瑞泽恩制药公司 | 用于靶向修饰基因组的方法和组合物 |
| LT3152312T (lt) * | 2014-06-06 | 2020-04-27 | Regeneron Pharmaceuticals, Inc. | Tikslinio lokuso modifikavimo būdai ir kompozicijos |
| EP3157956B1 (en) * | 2014-06-19 | 2020-02-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
| RU2771532C2 (ru) | 2014-06-26 | 2022-05-05 | Регенерон Фармасьютикалз, Инк. | Способы и композиции для нацеленных генетических модификаций и способы их применения |
| AU2015317370A1 (en) | 2014-09-19 | 2017-03-23 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
| KR20230070319A (ko) | 2014-11-21 | 2023-05-22 | 리제너론 파마슈티칼스 인코포레이티드 | 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물 |
| LT3689140T (lt) * | 2014-11-24 | 2022-08-25 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmones, ekspresuojantys humanizuotą cd3 kompleksą |
| BR112017013104A2 (pt) | 2014-12-19 | 2018-05-15 | Regeneron Pharma | métodos para modificar um locus genômico alvo em uma célula, para intensificar a recombinação homóloga em um locus genômico alvo em uma célula e para produzir uma geração f0 de um animal não humano. |
| AU2016246698B2 (en) * | 2015-04-06 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Humanized T cell mediated immune responses in non-human animals |
| EP3461337A1 (en) | 2015-05-06 | 2019-04-03 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
| MX2018005389A (es) | 2015-11-20 | 2018-09-05 | Regeneron Pharma | Animales no humanos que tienen un gen 3 de activacion linfocitaria humanizado. |
| CN109415687A (zh) * | 2016-04-07 | 2019-03-01 | 蓝鸟生物公司 | 嵌合抗原受体t细胞组合物 |
| MX2018012318A (es) | 2016-04-08 | 2019-07-04 | Immunocore Ltd | Receptores de celulas t. |
| CN116458475A (zh) * | 2016-06-03 | 2023-07-21 | 瑞泽恩制药公司 | 表达外源末端脱氧核苷酸转移酶的非人动物 |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| US20200171170A1 (en) * | 2017-06-16 | 2020-06-04 | Mayo Foundation For Medical Education And Research | Materials and methods for increasing immune responses |
| WO2019070541A1 (en) | 2017-10-03 | 2019-04-11 | Juno Therapeutics, Inc. | HPV-SPECIFIC BINDING MOLECULES |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| CA3094468A1 (en) * | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| EP3845638A4 (en) * | 2018-07-26 | 2022-05-11 | Kyoto University | METHOD FOR PRODUCING A CELL INTRODUCED BY A FOREIGN ANTIGEN RECEPTOR GENE |
| US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
| WO2021050948A1 (en) * | 2019-09-12 | 2021-03-18 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP2023504172A (ja) | 2019-12-02 | 2023-02-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用 |
| EP4126924A4 (en) * | 2020-03-27 | 2024-04-24 | 2Seventy Bio Inc | T CELL RECEPTORS |
| CN113684258A (zh) * | 2020-05-18 | 2021-11-23 | 上海赛比曼生物科技有限公司 | 用于检测鼠源tcr转基因拷贝数的试剂盒及方法 |
| BR112023018874A2 (pt) | 2021-03-31 | 2023-10-03 | Regeneron Pharma | Camundongos geneticamente modificados compreendendo componentes do sistema imunológico celular humanizado com diversidade melhorada do repertório de tcrb |
| US20240114883A1 (en) * | 2022-08-12 | 2024-04-11 | Ingenious Targeting Laboratories | Genetically modified non-human having humanized gamma and delta TCR variable genes |
| WO2024064860A1 (en) | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing components of human cellular immune system |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | TRANSGENIC NON-HUMAN ANIMALS WITH TARGETED INTERRUPTED TRANSDUCTION GENES IN LYMPHOCYTES. |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| WO1997032603A1 (en) | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
| US6320306B1 (en) * | 1996-08-05 | 2001-11-20 | Samsung Display Devices Co., Ltd. | Shadow mask with porous insulating layer and heavy metal layer |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| AU1023401A (en) | 1999-10-12 | 2001-04-23 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| US7462486B2 (en) | 2000-05-12 | 2008-12-09 | Oregon Health & Science University | Methods of selecting T cell receptor V peptides for therapeutic use |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2002222610A1 (en) | 2000-12-13 | 2002-06-24 | Sumitomo Pharmaceuticals Company, Limited | Transgenic animal expressing hla-a24 and utilization thereof |
| AU2002246733B2 (en) | 2000-12-19 | 2007-09-20 | Altor Bioscience Corporation | Transgenic animals comprising a humanized immune system |
| FR2827302B1 (fr) | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| PL208712B1 (pl) | 2001-08-31 | 2011-05-31 | Avidex Ltd | Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd |
| US20050177884A1 (en) | 2001-11-15 | 2005-08-11 | Kirin Beer Kabushiki Kaisha | Chimeric nonhuman animal |
| JP4238138B2 (ja) | 2001-12-22 | 2009-03-11 | ４−アンチボディ アーゲー | 遺伝的に修飾された脊椎動物前駆体リンパ球の生成方法及び異種結合タンパク質の産生を目的としたその使用。 |
| DK1321477T3 (da) | 2001-12-22 | 2005-02-14 | 4Antibody Ag | Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner |
| DE10244457A1 (de) | 2002-09-24 | 2004-04-01 | Johannes-Gutenberg-Universität Mainz | Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| AU2003279820A1 (en) | 2002-10-30 | 2004-06-07 | The Wistar Institute Of Anatomy And Biology | Mouse model for autoimmune disorders |
| US7663017B2 (en) * | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| PT1802193E (pt) | 2004-10-19 | 2014-06-23 | Regeneron Pharma | Método para gerar um murganho homozigótico para uma modificação genética |
| US20090304657A1 (en) | 2006-05-03 | 2009-12-10 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| US9388425B2 (en) | 2006-10-20 | 2016-07-12 | Trustees Of Boston University | Tunable genetic switch for regulating gene expression |
| JP2008159109A (ja) | 2006-12-21 | 2008-07-10 | Matsushita Electric Ind Co Ltd | データ転送装置 |
| US20090271884A1 (en) | 2008-03-07 | 2009-10-29 | Regeneron Pharmaceuticals, Inc. | ES Cell-Derived Mice From Diploid Host Embryo Injection |
| US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
| WO2010107400A1 (en) | 2009-03-20 | 2010-09-23 | Agency For Science, Technology And Research | Genetically modified animal and method of obtaining the same |
| DK3241435T3 (da) * | 2009-07-08 | 2021-08-23 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
| GB0917090D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| CA2777053A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| US9557323B2 (en) | 2010-09-24 | 2017-01-31 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
| US10765093B2 (en) | 2010-11-27 | 2020-09-08 | James Zhu | Humanized transgenic animal |
| DK3424947T3 (da) * | 2011-10-28 | 2021-02-22 | Regeneron Pharma | Genmodificerede t-celle-receptor-mus |
| AU2016246698B2 (en) | 2015-04-06 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Humanized T cell mediated immune responses in non-human animals |
-
2012
- 2012-10-26 DK DK18176096.8T patent/DK3424947T3/da active
- 2012-10-26 EP EP20198394.7A patent/EP3795587A1/en active Pending
- 2012-10-26 BR BR112014009203-6A patent/BR112014009203B1/pt active IP Right Grant
- 2012-10-26 CN CN202210507387.4A patent/CN114891798A/zh active Pending
- 2012-10-26 PT PT12784833T patent/PT2771357T/pt unknown
- 2012-10-26 DK DK12784833.1T patent/DK2771357T3/en active
- 2012-10-26 KR KR1020207024033A patent/KR102321909B1/ko active IP Right Grant
- 2012-10-26 ES ES18176096T patent/ES2858978T3/es active Active
- 2012-10-26 PL PL18176096T patent/PL3424947T3/pl unknown
- 2012-10-26 CN CN201280064216.3A patent/CN104011071B/zh active Active
- 2012-10-26 IL IL274914A patent/IL274914B2/en unknown
- 2012-10-26 MX MX2014004894A patent/MX353134B/es active IP Right Grant
- 2012-10-26 PL PL12784833T patent/PL2771357T3/pl unknown
- 2012-10-26 ES ES12784833T patent/ES2691475T3/es active Active
- 2012-10-26 KR KR1020227015694A patent/KR102542272B1/ko active IP Right Grant
- 2012-10-26 SI SI201231885T patent/SI3424947T1/sl unknown
- 2012-10-26 PT PT181760968T patent/PT3424947T/pt unknown
- 2012-10-26 LT LTEP12784833.1T patent/LT2771357T/lt unknown
- 2012-10-26 SG SG11201401030WA patent/SG11201401030WA/en unknown
- 2012-10-26 RU RU2014121160A patent/RU2661106C2/ru active
- 2012-10-26 RS RS20210210A patent/RS61455B1/sr unknown
- 2012-10-26 HU HUE18176096A patent/HUE053444T2/hu unknown
- 2012-10-26 SI SI201231413T patent/SI2771357T1/sl unknown
- 2012-10-26 EP EP12784833.1A patent/EP2771357B1/en active Active
- 2012-10-26 IN IN3890CHN2014 patent/IN2014CN03890A/en unknown
- 2012-10-26 EP EP18176096.8A patent/EP3424947B1/en active Active
- 2012-10-26 IL IL305550A patent/IL305550A/en unknown
- 2012-10-26 SG SG10201914043XA patent/SG10201914043XA/en unknown
- 2012-10-26 CN CN202210507359.2A patent/CN114891797A/zh active Pending
- 2012-10-26 AU AU2012327204A patent/AU2012327204B2/en active Active
- 2012-10-26 KR KR1020147014477A patent/KR101964776B1/ko active IP Right Grant
- 2012-10-26 KR KR1020217035333A patent/KR102397961B1/ko active IP Right Grant
- 2012-10-26 CN CN201710930556.4A patent/CN107858333B/zh active Active
- 2012-10-26 KR KR1020197008815A patent/KR102148387B1/ko active IP Right Grant
- 2012-10-26 RS RS20181207A patent/RS57893B1/sr unknown
- 2012-10-26 CN CN201710930555.XA patent/CN107858332A/zh active Pending
- 2012-10-26 LT LTEP18176096.8T patent/LT3424947T/lt unknown
- 2012-10-26 US US13/661,342 patent/US9113616B2/en active Active
- 2012-10-26 WO PCT/US2012/062065 patent/WO2013063361A1/en active Application Filing
- 2012-10-26 CA CA2853707A patent/CA2853707A1/en active Pending
- 2012-10-26 JP JP2014539033A patent/JP6254528B2/ja active Active
-
2014
- 2014-04-13 IL IL232098A patent/IL232098B/en active IP Right Grant
- 2014-11-19 HK HK14111660.0A patent/HK1198171A1/xx unknown
-
2015
- 2015-07-14 US US14/799,355 patent/US11528895B2/en active Active
-
2016
- 2016-04-20 AU AU2016202512A patent/AU2016202512C1/en active Active
-
2017
- 2017-10-24 JP JP2017205098A patent/JP6532924B2/ja active Active
-
2018
- 2018-06-28 AU AU2018204700A patent/AU2018204700C1/en active Active
- 2018-10-10 HR HRP20181626TT patent/HRP20181626T1/hr unknown
- 2018-10-16 CY CY181101057T patent/CY1120945T1/el unknown
- 2018-12-10 JP JP2018231026A patent/JP6706311B2/ja active Active
-
2020
- 2020-05-15 JP JP2020085787A patent/JP2020146045A/ja not_active Withdrawn
- 2020-10-27 US US17/081,470 patent/US20210051930A1/en active Pending
-
2021
- 2021-02-15 HR HRP20210256TT patent/HRP20210256T1/hr unknown
- 2021-02-19 CY CY20211100142T patent/CY1123831T1/el unknown
- 2021-05-18 AU AU2021203192A patent/AU2021203192B2/en active Active
-
2022
- 2022-05-02 JP JP2022075908A patent/JP7305840B2/ja active Active
- 2022-07-22 US US17/814,388 patent/US20220386575A1/en active Pending
- 2022-12-26 JP JP2022208112A patent/JP2023024744A/ja active Pending
-
2023
- 2023-12-20 JP JP2023214715A patent/JP2024019646A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210256T1 (hr) | Genetski modificirani mišji receptor t-stanice | |
| HRP20171357T1 (hr) | Ograničeni teški lanac imunoglobulina u miševa | |
| MX2023004169A (es) | Alteracion de la expresion genetica en celulas t modificadas con el receptor de antigeno quimerico (cart) y usos de las mismas. | |
| HRP20200305T1 (hr) | Genetski modificirani miševi koji eksprimiraju kimerne molekule glavnog histokompatibilnog kompleksa (mhc) ii | |
| HRP20171193T1 (hr) | Proizvodnja vezivnih molekula | |
| HRP20190807T1 (hr) | Miševi koji izražavaju imunoglobulinski hibridni laki lanac s humanom varijabilnom regijom | |
| HRP20171164T1 (hr) | Antigen-specifični t stanični receptori i t stanični epitopi | |
| JP2014532413A5 (hr) | ||
| HRP20150262T1 (hr) | Miševi sa adam6 | |
| HRP20191420T1 (hr) | Miševi koji su genetski modificirani s glavnim histokompatibilnim kompleksom | |
| BR112017005245A2 (pt) | animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos. | |
| BR112015021819A2 (pt) | Tratamento de câncer utilizando receptor quimérico de antígeno humanizado anti-cd19 | |
| FI3280257T3 (fi) | Humanisoituja t-soluvälitteisiä immuunivasteita ei-ihmiseläimillä | |
| MX2020001198A (es) | Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos. | |
| JP2014532411A5 (hr) | ||
| MX2018007295A (es) | Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos. | |
| JP2014532412A5 (hr) | ||
| RU2017134504A (ru) | Способ лечения рака | |
| JP2018513683A5 (hr) | ||
| BR112014006176A8 (pt) | Rna transcrito in vitro ou rna sintético, composição, método para gerar uma população de células t geneticamente modificadas por rna, e, uso de uma célula t geneticamente modificada | |
| JP2012532598A5 (hr) | ||
| NZ630551A (en) | Methods and means for the production of ig-like molecules | |
| BR112014008694A2 (pt) | moléculas de ácido nucleico policistrônico recombinante | |
| BRPI0513706A (pt) | anticorpo policlonal recombinante anti-rhesus d e métodos de produção | |
| MX367170B (es) | Enriquecimiento de la clasificacion de las celulas activadas por fluorescencia (facs) para generar plantas. |